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Summary
Butirosins A and B are naturally occurring aminogly-
coside antibiotics that have a (2S)-4-amino-2-hydroxy-
butyrate (AHBA) side chain. Semisynthetic addition of
AHBA to clinically valuable aminoglycoside antibiot-
ics has been shown both to improve their pharmaco-
logical properties and to prevent their deactivation by
a number of aminoglycoside-modifying enzymes in-
volved in bacterial resistance. We report here that the
biosynthesis of AHBA from L-glutamate, encoded
within a previously identified butirosin biosynthetic
gene cluster, proceeds via intermediates tethered to
a specific acyl carrier protein (ACP). Five components
of the pathway have been purified and characterized,
including the ACP (BtrI), an ATP-dependent ligase
(BtrJ), a pyridoxal phosphate-dependent decarboxyl-
ase (BtrK), and a two-component flavin-dependent
monooxygenase system (BtrO and the previously un-
reported BtrV). The proposed biosynthetic pathway
includes a -glutamylation of an ACP-derived -amino-
butyrate intermediate, possibly a rare example of pro-
tective group chemistry in biosynthesis.
Introduction
Aminoglycoside antibiotics constitute a clinically valu-
able class of compounds including kanamycin, neomy-
cin, and gentamycin. The bactericidal activity of such
antibiotics derives from their affinity for the bacterial
30S ribosomal subunit and their consequent interfer-
ence with protein synthesis by induction of codon mis-
reading and inhibition of translocation [1, 2]. Aminogly-
coside antibiotics are most commonly used to treat
infections by Gram-negative bacilli [3], but they also
show potentially useful activity against human immuno-
deficiency virus (HIV) [4, 5] and inhibit catalytic RNAs
such as the group I intron, the hammerhead ribozyme,
and the hepatitis delta virus (HV) ribozyme [6]. Amino-
glycoside resistance among target pathogens [7, 8] is
conferred in most cases by the expression of at least
one enzyme that chemically modifies the antibiotic
molecule [9] by O-phosphorylation, O-nucleotidylyla-
tion, or N-acetylation, thereby weakening rRNA bind-
ing. This has stimulated the search for semisynthetic*Correspondence: jbs20@cam.ac.ukaminoglycoside analogs, such as amikacin, (Figure 1)
which can overcome these resistance mechanisms
[10]. An attractive alternative approach to the develop-
ment of new, more potent antibiotics is the genetic ma-
nipulation of existing biosynthetic pathways to incorpo-
rate beneficial structural modifications. To pursue this,
we have sought to elucidate the biosynthetic pathway
for butirosin.
The butirosins (Figure 1) from Bacillus circulans [11]
contain a 4,5-disubstituted 2-deoxystreptamine (2-DOS)
core with a neosamine C ring at 4-O and either a xylose
(Butirosin A) or ribose (Butirosin B) sugar at 5-O. They
are unique among naturally occurring aminoglyco-
sides in that they bear a (2S)-4-amino-2-hydroxybutyryl
(AHBA) moiety on the C-1 amine of the 2-DOS ring. This
modification has been shown to confer resistance
against several aminoglycoside-modifying enzymes [12].
Indeed, the butirosins have demonstrated activity to-
ward many strains that have developed resistance
to other structurally similar aminoglycosides [11, 13].
Although the butirosins are not themselves clinically
useful drugs, recognition of the valuable AHBA modifi-
cation has led to successful synthetic alteration of kana-
mycin and dibekacin to produce amikacin and arbe-
kacin, respectively. The C-1 amine is a frequent target
of aminoglycoside N-acyltransferases, and the AHBA
modification prevents drug deactivation by this class
of enzymes while also improving the pharmacological
profile of the drug beyond that of the parent molecule.
The biosynthesis of AHBA has been the subject of con-
siderable speculation, and a partial gene cluster for
butirosin biosynthesis containing 17 ORFs (btrA–btrQ)
in a region of 18 kbp has been identified in B. circulans
[14]. However, the enzymatic pathway leading to AHBA
and to its integration into the complete butirosin mol-
ecule has not been clearly characterized. Feeding
studies have shown that L-glutamate and γ-aminobuty-
rate (GABA) are incorporated into the butirosins in
B. circulans but not AHBA, suggesting that free AHBA
is not a precursor of the butirosins [15]. This finding
contradicts an earlier report suggesting the direct addi-
tion of AHBA to the DOS amine based on an apparent
in vitro enzymatic AHBA-dependent ATP-PPi exchange
in extracts of butirosin-producing B. circulans [16]. The
observation of ATP-PPi exchange is suggestive of car-
boxyl-group activation and, possibly, amide-bond for-
mation as seen in nonribosomal peptide synthetases.
In this paper, we report the heterologous expression
and functional characterization of the enzymes respon-
sible for the synthesis of AHBA via acyl carrier protein
(ACP)-mediated intermediates.
Results
A gene cluster putatively responsible for butirosin bio-
synthesis was previously reported, and three genes,
btrI, btrJ, and btrK were proposed to encode proteins
involved in the synthesis of AHBA based on the sim-
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666Figure 1. Molecular Structures of Aminoglycoside Antibioticsilarity of their deduced peptide sequences to those of u
nknown enzymes [14]. Comparison with the neomycin
biosynthetic gene cluster [17] shows that btrG, btrH, b
abtrI, btrJ, btrK, and btrO are unique to the butirosin
cluster (Figure 2), suggesting that some or all of these n
pgenes relate to the synthesis and transfer of AHBA,
which is not present in neomycin. Further, gene walking were heterologously expressed in Escherichia coli BL-
Figure 2. Comparison of Butirosin and Neomycin Gene Clusterspstream of the btrA gene in the butirosin cluster has
ow revealed another open reading frame unique to the
utirosin cluster, btrV. The genes btrI, btrJ, btrK, btrO,
nd btrV have been successfully amplified from the ge-
omic DNA of B. circulans NR3312 and cloned into
ET-28(a)+ with appropriate restriction sites. Proteins
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66721(DE3) with N-terminal His6 tags. Proteins were initially
purified by nickel-affinity chromatography and further
purified to homogeneity as necessary.
Characterization of BtrI
Carrier proteins such as acyl, peptidyl, and aryl carrier
proteins (ACPs/PCPs/ArCPs) are central entities of sev-
eral multifunctional enzyme complexes, including fatty
acid synthases (FASs), polyketide synthases (PKSs),
and nonribosomal polypeptide synthetases (NRPSs)
[18, 19]. The functional forms of these carrier proteins
bear an essential 4#-phosphopantetheine (4#-PP) pros-
thetic arm covalently bound to an active site serine res-
idue. The terminal cysteamine thiol of the 4#-PP moiety
serves as a nucleophile to attack the activated acyl
group, thereby linking the substrate and the carrier pro-
tein via a thioester bond. BtrI is a small protein of 87
amino acids (9.8 kDa) that exhibits homology to several
ACPs from PKS systems and conserves the signature
LGXDSX sequence of the 4#-PP binding domain. BtrI is
most homologous to an ACP domain from a mixed type
I PKS/NRPS in a symbiont bacterium of Paederus fus-
cipes beetles (33% identity, 58% similarity) [20] and to
a putative methoxymalonyl-ACP involved in geldana-
mycin biosynthesis in Streptomyces hygroscopicus
(34% identity, 57% similarity) [21]. BtrI is also distantly
related to a D-alanyl carrier protein involved in lipo-
teichoic-acid biosynthesis [22]. BtrI does not demon-
strate significant homology to other carrier proteins
(PCPs/ArCPs); this is unsurprising because sequence
analysis has revealed that ACPs share little similarityFigure 3. 4#-Phosphopantetheinylation of BtrI
LC and MS traces of (A) apo-BtrI and (B) holo-BtrI produced by incubation of apo-BtrI with Sfp and CoA.with PCPs beyond the highly conserved region around
the conserved serine residue of the 4#-PP binding do-
main to which 4#-PP transferases (PPTases) transfer
4#-PP from coenzyme A (CoASH) [23].
For confirmation that BtrI is an acyl carrier protein, in
vivo and in vitro phosphopantetheinylation assays were
carried out to test whether BtrI is a substrate for
PPTases. N-terminally His6-tagged BtrI was well ex-
pressed in E. coli with high yields (10 mg/l culture). LC-
ESI-MS confirmed that the majority of the purified BtrI
has a molecular mass of 11,812.0 Da (Figure 3A), corre-
sponding to the apo-form (calculated at 11,813.25 Da,
His6 tag inclusive). Less than 10% was shown to be in
the active holo-form. Thus, it appears that BtrI is a poor
substrate of endogenous E. coli PPTases such as AcpS
[24]. Therefore, the broad-spectrum PPTase Sfp from
B. subtilis, which exhibits activity toward PCPs as well
as ACPs in both primary and secondary metabolism
[25], was chosen for the phosphopantetheinylation as-
say. Sfp was overexpressed in E. coli and purified to
near homogeneity as described in Experimental Pro-
cedures. Upon incubation with CoASH and Sfp for 15
min, apo-BtrI was almost fully converted to the holo-
form, having a molecular mass of 12,153.0 Da in accor-
dance with the calculated 12,152.57 Da as shown by
LC-ESI-MS (Figure 3B). BtrI was coexpressed with Sfp
in E. coli in order to prove that it is a substrate of
PPTase in vivo as well. The coexpression vector was
derived from pET-28a(+) with each gene under the con-
trol of its own T7 promoter. The coexpressed BtrI
yielded one major peak (>95%) by LC-ESI-MS, corre-
sponding to the holo-form, and a minor peak corre-
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Mthat the PPTase Sfp can recognize apo-BtrI as a sub-
strate and transfer the 4#-PP moiety from CoASH into d
wholo-BtrI both in vivo and in vitro.
i
dActivation and Loading of L-Glutamate
The deduced amino acid sequence of BtrJ (419 amino i
macids, 48.6 kDa) shows weak local similarity to that of
biotin carboxylase (32% identity) [26] and of the large B
asubunit of carbamoyl phosphate synthase (26% iden-
tity) [27]. Both enzymes belong to the growing ATP- B
mgrasp superfamily as classified by their three-dimen-
sional structures. Other members of this superfamily B
ainclude D-alanine:D-alanine ligase [28], glutathione syn-
thetase [29], glycinamide ribonucleotide transformylase c
l[30], and succinyl-CoA synthetase [31]. Despite low se-
quence homology, enzymes in this superfamily exhibit t
fa characteristic motif for ATP binding and invariably
possess ATP-dependent carboxyl-amine or carboxyl- b
thiol ligase activity. The reaction mechanism is pro-
posed to involve the generation of an acylphosphate D
Fintermediate via hydrolysis of ATP to ADP [28, 29].
The N-terminal His6-tagged BtrJ is a monomeric pro- t
atein with a molecular mass of 50,962.0 Da (calculated
at 50,969.05) as measured by LC-ESI-MS. The purified b
nprotein was liable to aggregation in solution, and the
presence of dithiothreitol (DTT) was found to be neces- n
lsary to prevent this. BtrJ was initially proposed to cata-
lyze formation of the amide bond between AHBA and b
Eribostamycin, but when BtrJ was incubated with ATP,
AHBA, and ribostamycin in the presence of Mg2+, no i
tproduction of butirosin was detectable, apparently indi-
cating that BtrJ is involved in a different ligation reac- n
stion. Because recent feeding studies revealed that la-
beled L-glutamate and GABA but not AHBA were T
tincorporated into butirosin [15], we reasoned that BtrJ
might catalyze activation of a carboxyl precursor and s
iits subsequent transfer to holo-BtrI, yielding an acyl-
S-BtrI product. The ADP-forming activity of BtrJ was t
Vcoupled to the reactions of pyruvate kinase (PK) and
NADH-dependent lactate dehydrogenase (LDH) and a
omeasured spectrophotometrically to test this hypothe-
sis. A significant decrease in absorbance at 340 nm u
Bwas observed only when L-glutamate was added to the
reaction mixture, which contained 1 mM ATP, 5 mM t
wMgCl2, 5 mM MnCl2, 50 mM KCl, BtrJ, and the PK/LDH
coupling components. Incubation with GABA, AHBA, or n
aD-glutamate did not lead to significant spectral changesFigure 4. γ-L-Glutamylation of BtrI
LC and MS traces of γ-L-glutamyl-S-BtrI produced by incubation of holo-BtrI with BtrJ and L-glutamate.ompared to a blank control. Divalent ions, such as
g2+ or Mn2+, are essential for the L-glutamate-depen-
ent ATPase activity of BtrJ, and the presence of Mn2+
as found to stimulate the reaction rate. These results
mply the generation of a glutamyl-phosphate interme-
iate. Loading of L-glutamate onto BtrI was conducted
n a 50 l reaction composed of 10 mM L-glutamate, 5
M ATP, 5 mM Mg2+, 5 mM Mn2+, 50 mM KCl, holo-
trI, and BtrJ. The mixture was analyzed by LC-ESI-MS
nd revealed a new peak eluting 1 min earlier than holo-
trI (Figure 4). It was observed to have a molecular
ass of 12,281.0 Da, matching closely that of L-Glu-S-
trI (calculated at 12,281.68 Da). The yield of glutamyl-
tion of BtrI was ~30% under these conditions. Be-
ause the pathway to AHBA from glutamate is most
ikely to include a decarboxylation step, we reasoned
hat the α-carboxyl group of L-glutamate would remain
ree while the γ-carboxyl group would be thioester
ound to BtrI.
ecarboxylation and Hydroxylation of the Acyl-ACP
MNH2-dependent two-component monooxygenase sys-
ems have been reported to catalyze monooxygenation of
liphatic substrates. Members of such systems include
acterial luciferase [32], pristinamycin IIA synthase [33],
itrilotriacetate monooxygenase [34], and alkanesulfo-
ate monooxygenase [35], which are involved in chemi-
uminescence reactions, antibiotic biosynthesis, xeno-
iotic degradation, and sulfur metabolism, respectively.
ach enzyme system features a two-component organ-
zation, composed of an oxidoreductase that catalyzes
he reduction of FMN with NAD(P)H as an electron do-
or and a monooxygenase that hydroxylates the sub-
trate in the presence of FMNH2 and molecular oxygen.
he oxidoreductase provides the monooxygenase with
he necessary reduced FMN cosubstrate. Although low
equence similarity is found between monooxygenases
n these systems at the amino acid level, available
hree-dimensional structures, including luciferase from
ibrio harveyi (LuxAB) and alkanesulfonate monooxygen-
se from E. coli (SsuD), exhibit strikingly similar structural
rganization distinct from the structures of enzymes that
tilize FMN as a prosthetic group and not as a substrate.
trO (341 aa, 38.7 kDa) exhibits 26% sequence identity to
he alkanesulfonate monooxygenase SsuD in B. subtilis,
hich is involved in oxygen-mediated cleavage of sulfo-
ate to sulfite via an α-hydroxy intermediate. BtrO is
lso predicted to be structurally related to SsuD and
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gene btrO in the butirosin cluster and encodes a protein
homologous to an NAD(P)H oxidoreductase in Bacillus
cereus (48% identity). Therefore, it is proposed that
BtrO and BtrV might together constitute a two-compo-
nent monooxygenase system.
The purified BtrV was found to be a homotetramer
with a monomeric molecular mass of 26.1 kDa (226 aa).
It is bright yellow in color, and UV-visible spectroscopy
reveals absorbance maxima at 377 and 454 nm, typical
of a flavin cofactor. In order to determine the identity of
the flavin cofactor, BtrV was precipitated with acetone.
HPLC analysis of the supernatant showed a single peak
with a retention time identical to that of the FMN stan-
dard rather than the FAD standard. ESI-MS confirmed
the cofactor to be FMN. Assays of oxidoreductase ac-
tivity were followed spectrophotometrically with FMN
and NADH, and the effect of pH on BtrV activity was
investigated over the range of 4.0–10.5. BtrV is most
active in sodium acetate buffer at pH 5.0. Kinetic
studies indicate that BtrV obeys typical Michaelis-Men-
ten saturation kinetics (for NADH in the presence of
FMN, kcat = 1243.13 min−1, KM = 6.86 M). BtrV is able
to oxidize both NADH and NADPH at comparable rates;
however, substrate inhibition was observed for NADPH,
suggesting that NADH is the preferred substrate. Ki-
netic data also indicated that FMN is favored over FAD
(for NADH in the presence of FAD, kcat = 887.48 min−1,
KM = 7.25 M). Therefore, BtrV is characterized as an
NAD(P)H:FMN oxidoreductase.
The purified BtrO was colorless, showing no spectral
absorbance typical of flavin cofactors. This observation
agrees with the proposition that BtrO utilizes FMNH2 as
a free coenzyme instead of a bound prosthetic group.
SDS-PAGE showed the 40 kDa His6-tagged BtrO to ac-
count for w70% of the eluted protein. ESI-MS con-
firmed its molecular mass to be 40,771.0 Da (calculated
at 40,772.32). BtrO was tested against several free
acids, including L-glutamate, L-aspartate, GABA, and
L-ornithine, under a variety of conditions; no hydroxyla-
tion products were detectable by TLC or HPLC, consis-
tent with the proposed ACP-mediated pathway. It was
expected that Sfp, which has been reported to promis-
cuously load various acyl- and peptidyl-CoA substrates
onto carrier proteins [25], could modify BtrI with syn-
thetic acyl-CoA derivatives to afford various acyl-S-BtrI
complexes in order to assay BtrO against authentic
ACP bound substrates. However, attempts to assay
BtrO activity against a synthetic sample of of γ-L-Glu-S-
BtrI were hindered by the lability of γ-L-Glu-CoA. Upon
incubation of BtrO and BtrV with γ-L-Glu-S-BtrI gener-
ated by BtrJ, no hydroxylation product was detected,
which would suggest that decarboxylation occurs first
and that GABA-S-BtrI is the substrate for BtrO. Al-
though GABA-CoA also proved unstable, enough syn-
thetically prepared GABA-S-BtrI was obtained to assay
with BtrO; surprisingly, no hydroxylation product was
detected in this case, either. Given the apparent unre-
activity of BtrO toward either of the likely substrates,
an activity assay was devised with butyryl-S-BtrI. Bu-
tyryl-S-BtrI was selected as a model substrate based
on three considerations: (1) the butyryl moiety is a
structural analog of GABA; (2) butyryl-S-BtrI is easily
produced in large quantity by the action of the PPTaseSfp with apo-BtrI and butyryl-CoA; (3) and it is conve-
nient to determine the position and stereochemistry of
the hydroxyl group by assay with LDH. Apo-BtrI was
modified by Sfp in the presence of butyryl-CoA to effi-
ciently generate butyryl-S-BtrI. Incubation of butyryl-
S-BtrI with BtrO and BtrV led to a new peak by LC-
ESI-MS with a mass of 12,240.0 Da eluting earlier than
butyryl-S-BtrI, whose measured mass was 12,224.0 Da
(Figure 5). The calculated masses for hydroxybutyryl-
and butyryl-S-BtrI are 12,238.65 and 12,222.66 Da,
respectively. Therefore, the new product, obtained in an
estimated yield of ~50%, corresponds to hydroxybu-
tyryl-S-BtrI. When the reaction was conducted under
anaerobic conditions or when FMN was replaced with
FAD, no hydroxylation product was detected, indicating
that FMNH2 and molecular oxygen are required for BtrO
activity. Moreover, BtrO showed no activity at all with
free butyrate or with butyryl-CoA, further supporting
the idea that BtrI is crucial for recognition and that a
significant protein-protein interaction between BtrO
and BtrI must exist. BtrO was also observed to hydrox-
ylate octyryl-S-BtrI (data not shown), suggesting that
the enzyme can accept longer chains as substrates.Figure 5. Hydroxylation of Butyryl-S-BtrI
LC and MS traces of butyryl-S-BtrI and 2-hydroxybutyryl-S-BtrI
produced by incubation of apo-BtrI with Sfp and butyryl-CoA fol-
lowed by addition of BtrO and BtrV.
Chemistry & Biology
670The position and stereochemistry of the hydroxyl v
lgroup were determined enzymatically by incubation
with LDH. Hydroxybutyrate was hydrolyzed from BtrI m
sunder alkaline conditions and extracted as described
in Experimental Procedures. The extracts were dis- i
tsolved in 100 l buffer containing NAD+ and L- or D-LDH.
After 70 min incubation, the absorbance at 340 nm t
mof the L-LDH reaction increased from 0.12 to 0.60,
whereas that of the D-LDH reaction remained nearly un- s
changed (0.12 to 0.17). These results indicate that the
extracted hydroxybutyrate is a substrate of L-LDH but a
anot D-LDH, therefore confirming that hydroxylation oc-
curs at the α-carbon of the butyryl moiety and that the H
oproduct has the S configuration, in agreement with the
known structure of butirosin. Given the reluctance of a
bthe monooxygenase system to react with any of the
expected native substrates and the efficient reactivity c
ctoward butyryl-S-BtrI, which lacks a γ-amine, we began
to suspect that an alternative substrate may be in- r
dvolved in the biosynthetic pathway and turned to the
decarboxylation step in search of answers. 3
cBtrK (428 aa, 47.8 kDa) exhibits significant homology
to the ornithine/arginine/diaminopimelate (DAP) decar- M
aboxylase family members, which are pyridoxal 5#-phos-
phate (PLP) dependent. In these enzymes, the PLP co- e
Dfactor is covalently bound to an essential lysine residueFigure 6. Decarboxylation of γ-L-Glu-S-BtrI
LC and MS traces of the BtrJ γ-glutamylation reaction mixture after addition of (A) BtrK, producing γ-L-Glu-GABA-S-BtrI, (B) EDTA and then
BtrK, producing GABA-S-BtrI, and (C) BtrK and then BtrO and BtrV, producing γ-L-Glu-AHBA-S-BtrI.ia a Schiff base. The purified BtrK appears bright yel-
ow in color. UV-visible spectroscopy of BtrK reveals a
aximum absorbance at 420 nm, consistent with the
pectrum of an internal aldimine of PLP. Gel filtration
ndicates that PLP and BtrK coelute, confirming that
he PLP cofactor is tightly bound to BtrK. The His6-
agged BtrK was found to be a homodimer with a mono-
er mass of 49,846.0 Da (calculated at 49,847.68 inclu-
ive of bound PLP), as confirmed by LC-ESI-MS.
Initial activity assays demonstrated that BtrK was
ble to decarboxylate L-ornithine, L-arginine, L-lysine,
nd DAP but not L-glutamate or any D-amino acids.
owever, this very weak decarboxylation activity was
nly seen at high substrate concentrations (>10 mM)
nd after extended incubation (>12 hr), as compared to
lank reactions without BtrK. Because of the low effi-
iency and low specificity of decarboxylation, we con-
luded that these free amino acids are probably not the
eal substrates of the enzyme. When BtrK was added
irectly to the BtrJ reaction mixture and incubated for
0 min, LC-ESI-MS revealed that γ-L-Glu-S-BtrI was
ompletely converted to a new product (Figure 6A).
ost surprisingly, the mass of this product (observed
t 12,370.0 Da) was significantly greater than that of the
xpected GABA-S-BtrI product (calculated at 12,237.67
a). The mass difference could correspond to a gluta-
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Leading to Butirosins A and Bmate residue; thus, the new product is proposed to be
γ-L-Glu-GABA-S-BtrI (calculated at 12,366.85 Da). One
possible explanation of this result could be that the
still-present BtrJ is able to catalyze ligation of a second
L-glutamate molecule to GABA-S-BtrI, forming an am-
ide bond. The GABA-S-BtrI is closely related to holo-
BtrI in structure; therefore, it is reasonably likely to fit
into the active site of BtrJ. Another possibility is that it
could result from a nonenzymatic nucleophilic attack
by the amino group of GABA-S-BtrI toward the acti-
vated acyl-phosphate intermediates generated by BtrJ.
However, the latter scenario is unlikely based on the
observation that there is no γ-L-Glu-γ-L-Glu-S-BtrI pro-
duced in the BtrJ assay. For the same reason, it is also
unlikely that the observed BtrK product is GABA-γ-L-
Glu-BtrI. It is expected, then, that if BtrJ is inactivated
before addition of BtrK, GABA-S-BtrI should be ob-
tained. Indeed, when the reaction mixture of BtrJ was
incubated with EDTA prior to addition of BtrK, the BtrK
assay yielded the expected GABA-S-BtrI product with
an observed mass of 12,240.0 Da, coeluting with unre-
acted γ-L-Glu-S-BtrI (12,284.0 Da) (Figure 6B).
The production of γ-L-Glu-GABA-S-BtrI by the com-
bined action of BtrJ and BtrK strongly supports the
contention that BtrO, showing no activity toward the
most likely substrates, must act on an alternative sub-
strate. The γ-glutamylation of GABA neutralizes the ex-
pected positively charged amine of GABA, consistent
with the observed reactivity of BtrO toward the elec-
tronically neutral butyryl substrate as well as the longer
neutral octyryl substrate. Indeed, BtrO is able to ef-
ficiently hydroxylate γ-L-Glu-GABA-S-BtrI: after a 30
min reaction, complete conversion of available γ-L-
Glu-GABA-S-BtrI to γ-L-Glu-AHBA-S-BtrI (observed at
12,384.0 Da; calculated at 12,382.85 Da) was observed
(Figure 6C). Therefore, we conclude that γ-L-Glu-GABA-
S-BtrI is the real substrate for BtrO.
To date, BtrG and BtrH have not yet been success-
fully expressed in E. coli as soluble, active enzymes,
and efforts toward the characterization of these two en-
zymes continue.Discussion
We report here the characterization of five enzymes in-
volved in the biosynthesis of (2S)-4-amino-2-hydroxy-
butyrate (AHBA). Our results suggest a novel ACP-
mediated biosynthetic route (Figure 7). The L-glutamate
is first activated and tethered to BtrI via a thioester link-
age between its γ-carboxyl group and the terminal sulf-
hydryl group of the 4#-PP arm of BtrI. Decarboxylation
and α-hydroxylation occur sequentially on acyl-S-BtrI
intermediates. Most distinctly, AHBA is produced ex-
clusively with a γ-glutamyl substituent on the amino
group. This may be a protective mechanism that pre-
vents the amino group of GABA-S-BtrI from undergoing
nucleophilic attack on the carbonyl group, leading to
self-cyclization and premature cleavage from the ACP.
A similar protection mechanism appears to operate
in a recently described bacterial putrescine utilization
pathway in which putrescine is γ-glutamylated prior to
oxidation to γ-glutamyl-γ-aminobutyraldehyde [36]; with-
out the γ-glutamyl protective group, the γ-aminobutyral-
dehyde would likely self-cyclize, interfering with further
transformations. Furthermore, the γ-glutamyl moiety may
provide additional protection to the producing organ-
ism against the butirosin it produces. It is therefore pro-
posed that the cleavage of the γ-glutamyl group occurs
in the final step of butirosin biosynthesis. This pathway
agrees with the results of feeding studies demonstrating
that L-glutamate is a precursor of butirosin, whereas
free AHBA is not. Although these feeding studies also
indicated GABA to be a precursor, this is likely the re-
sult of the in vivo interconversion of GABA and L-gluta-
mate via a succinate intermediate [37].
BtrI plays an essential central role in the AHBA syn-
thetic pathway, carrying the γ-glutamyl moiety via a thio-
ester linkage and functions as a platform on which
modifications of L-glutamate occur. BtrI shows se-
quence homology to ACPs but not PCPs. Unlike neutral
PCPs, which are buried among multiple domains, BtrI
is discrete and acidic (calculated pI 4.30), resembling
type II ACPs. The charged protein surface may be cru-
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teins. γ-carboxyl-activated glutamate is liable to un- s
dergo cyclization, forming pyrrolidone carboxylate, or m
hydrolysis; however, compared to chemically synthe- G
sized γ-glutamyl-CoA thioester, γ-L-Glu-S-BtrI demon- f
strates unusual stability. This stability suggests that BtrI
may provide essential hydrogen bonding sites to form (
a stabilizing environment for the γ-glutamyl moiety. The a
solution structure of a type II PKS ACP (actinorhodin a
ACP) reveals that residue Arg72 is partially buried in p
the hydrophobic core, suggesting a potential hydrogen g
bonding site for unstable polyketide intermediates [38]. s
This arginine residue is conserved in all PKS ACPs as a
well as in BtrI (Arg73) and, therefore, might serve the p
same stabilizing function. p
BtrI is absolutely required for the function of other g
enzymes in this pathway, suggesting strong protein- q
protein interactions between BtrI and its partner en- β
zymes. Although the structures of the PPTase Sfp [39], A
the phenylalanine-activating A domain of gramicidin S t
synthetase I [40], and several ACP/PCPs are available, a
just how PCPs and ACPs interact with other proteins s
remains unknown. BtrJ is unable to γ-glutamylate one l
of BtrI’s predicted structural homologs, the actino- m
rhodin ACP. Likewise, BtrI cannot replace the actino- s
rhodin ACP in actinorhodin biosynthesis (Dr. H. Hong, b
personal communication), implying that specificity of c
recognition may result from rather subtle structural dif- p
ferences. A recent docking simulation of an acyl-ACP p
dehydrogenase (FkbI) and its cognate ACP (FkbJ) re- p
vealed that the conserved Leu residue in the D-S-L mo- B
tif of the ACP was placed into a hydrophobic pocket m
formed by FkbI [41]. Moreover, a conserved Asp resi- e
due of FkbJ formed a salt bridge to an Arg residue con- m
served in FkbI orthologs but not in most acyl-CoA de- m
hydrogenases. Such conserved interface interactions t
ought to exist between BtrI and its partner proteins. t
Taken together, our results suggest that further decod-
ing of the protein-protein interactions in the AHBA bio- g
synthetic pathway might well facilitate construction of t
hybrid enzyme systems that may allow attachment of t
AHBA to different substrates and, hence, produce s
novel aminoglycosides directly by fermentation. G
BtrJ is a enzyme of dual function that selectively acti-
a
vates the γ-carboxyl group of L-glutamate and catalyzes
b
two ligation reactions of γ-L-glutamate to holo-BtrI and
sto GABA-S-BtrI, respectively. BtrJ is functionally analo-
gous to adenylation (A) domains in NRPSs; however,
SBtrJ does not show sequence similarity to any A do-
mains. Moreover, BtrJ activates the carboxyl group via
Tan acylphosphate intermediate, a different mechanism (from that of the A domains, which utilize aminoacyl-
oAMP intermediates. To our knowledge, BtrJ is the first
tcharacterized enzyme that catalyzes activation of the
pγ-carboxyl group of L-glutamate and formation of a
sγ-L-Glu-S-ACP species. There is only one correspond-
eing example known in the A domains: the A domain
Bof the mixed PKS/NRPS McyE in microcystin biosyn-
tthesis is proposed to load the γ-carboxyl group of
oD-glutamate onto a PCP domain [42]. The amide-form-
cing activity of BtrJ resembles that of γ-glutamylcysteine
asynthetase in glutathione biosynthesis, which catalyzes
sγ-glutamylation of cysteine [43]. Both enzymes are pre-
dicted to belong to the ATP-grasp superfamily based in their similar carboxyl activation mechanism. The
tructural similarity between the terminal cysteamine
oiety of the 4#-PP arm and the terminal amine of
ABA may be a prerequisite determinant for the dual
unction of BtrJ.
The molecular logic utilized by these five enzymes
BtrI, BtrJ, BtrK, BtrO, and BtrV) to activate and modify
precursor docked on an ACP has been observed
nalogously in other biosynthetic pathways. For exam-
le, the sets of genes asm13–asm17, fkbG–fkbK, and
dmG–gdmK have been identified as factors in the bio-
ynthesis of the 2-methoxymalonyl extender unit in the
nsamitocin [44], FK520 [45], and geldanamycin [21]
athways, respectively. These reactions have been pro-
osed to proceed through activation and ligation of a
lycolytic intermediate onto an ACP followed by subse-
uent transformations. Analogously, in some NRPSs
-hydroxylation occurs on amino acids preattached to
-PCP didomains. Our results lend further weight to
he suggestion that the utilization of acyl-S-enzyme or
minoacyl-S-enzyme species is a common strategy to
equester primary metabolites for secondary metabo-
ism [46]. These results may also implicate similar ACP-
ediated pathways in the biosynthesis of nonstandard
tarter units in polyketide synthesis. For example, in the
iosynthetic cluster for the polyketide macrolactam vi-
enistatin in Streptomyces halstedii, among the gene
roducts thought to be involved in the formation of the
recursor of the starter unit (2R)-2-methyl-3-amino-
ropionate are a putative discrete ACP (VinL) and a
trK homolog (VinO) [47]. Based on our results, one
ay propose a similar pathway of decarboxylation and
pimerization occurring on the precursor (2S, 3S)-3-
ethylaspartate thioester carried by VinL. The (2R)-2-
ethyl-3-aminopropionyl moiety tethered to VinL is
hen specifically transferred to the loading module of
he PKS by so-called ACP-to-ACP skipping [47].
The activities of the remaining two enzymes from this
ene cluster, BtrG and BtrH, have not yet been charac-
erized. Neither enzyme bears significant homology
o any known proteins. Given that the five enzymes
tudied here are sufficient for the biosynthesis of γ-L-
lu-GABA-S-BtrI, we postulate that these two enzymes
re responsible for the transfer of the acyl chain to ri-
ostamycin/xylostasin and deglutamylation as the final
teps in butirosin biosynthesis.
ignificance
he modification of aminoglycoside antibiotics with
2S)-4-amino-2-hydroxybutyrate (AHBA) has previ-
usly been shown to help overcome bacterial resis-
ance mechanisms and to improve pharmacological
roperties. Here, AHBA is shown to be biosynthe-
ized from L-glutamate via an ACP-mediated pathway
ncoded within the butirosin synthetic gene cluster.
iosynthesis is demonstrated to proceed by -glu-
amylation of the ACP BtrI by BtrJ, decarboxylation
f the resulting acyl-ACP by the PLP-dependent de-
arboxylase BtrK, and subsequent hydroxylation by
two-component FMN-dependent monooxygenase
ystem composed of BtrO and BtrV. Surprisingly, BtrJ
s found to catalyze a second -glutamylation of the
Biosynthesis of (2S)-4-Amino-2-Hydroxybutyrate
673GABA-S-BtrI intermediate produced in the decarbox-
ylation step; this activity may represent an unusual
example of protective-group chemistry in an enzy-
matic system. The number of protein-protein interac-
tions apparent in this system offers a valuable oppor-
tunity to study the determinants of such interactions
in this and similar ACP-mediated systems. Further-
more, the characterization of this pathway will poten-
tially allow the movement of these genes into other
aminoglycoside-producing organisms to provide both
known and novel derivatives directly by fermentation.
Experimental Procedures
Cloning of Butirosin Biosynthetic Genes and Heterologous
Overexpression of Enzymes
The genes btrG, btrH, btrI, btrJ, btrK, btrO, and btrV were amplified
by PCR from genomic DNA of Bacillus circulans NR3312 with the
following pairs of primers, respectively (restriction sites are un-
derlined): forward pG1 5#-CGTAAGTGAGTTTAAGCATATGAT-TAG
CTGGACGAA-3# (NdeI) and reverse pG2 5#-GCGATTTTCTGCA
CTCGAGAAATTTCTCGTCATAAC-3# (XhoI); forward pH1 5#-AGA-
GGAGAAGCCATATGTGCCTCACTCGTTA-TGACG-3# (NdeI) and
reverse pH2 5#-TCCTTCTGTATGGGATCCCGGTTTCCGCACAGC
GGT-3# (BamHI); forward pI1 5#-CAGAAGGAGTTGAATCATATGTCT
TTAGAAACTC-3# (NdeI) and reverse pI2 5#-TCCAGCGGATGAG
GGATCCTCATAGGG-3# (BamHI); forward pJ1 5#-ACGTCTATGCT
AGCATGAAGTTCACTCATCCGCTGG-3# (NheI) and reverse pJ2 5#-
CTCGATCCTCGAGCCCTCCCTTCTTCATGAGTTAAT-3# (XhoI); for-
ward pK1 5#-GGGATTTGCATATGAACCTGGATCAAGCTG-3# (NdeI)
and reverse pK2 5#-CGTATATTGGAATTCCTATTTGTCCAT-3# (EcoRI);
forward pO1 5#-ATACGAAAAGCAGGCATATGATTGCATTGG-3# (NdeI)
and reverse pO2 5#-GTTTGCTCGCGGTCGGATCCCTAGAC-3# (BamHI);
and forward pV1 5#-AAAAATAACATATGGGAAAGGAGAGT-GAT-3#
(NdeI) and reverse pV2 5#-TTATACTCTCTCGAGATCCGAACGTCA
CAT-3# (XhoI). The gene Sfp was PCR amplified from genomic DNA
of Bacillus subtilis with the forward primer 5#-AATCAACATATG
AAGATTTACGGAATTTATATGGACCGC-3# (NdeI) and the reverse
primer 5#-CCTACTCTCGAGTTGAGCGCGGTGTCAAGCTGTTG-3#
(XhoI).
PCR reactions were carried out as follows with Pfu polymerase
(Stratagene): 4 min at 94°C, 1 min at 94°C, 1 min at 60°C, 2 min at
72°C for 25 cycles, and the final extension at 72°C for 10 min. The
amplified genes were cloned into appropriate restriction sites of
pET-28a(+) and transformed into E. coli BL21(DE3) for overexpres-
sion. All constructs were checked by DNA sequencing.
Overexpression and Purification of Recombinant BtrI,
BtrJ, BtrK, BtrO, BtrV, and Sfp
One liter of culture in LB medium of E. coli BL21(DE3) harboring
recombinant plasmid was grown at 37°C for 3 hr with kanamycin
selection (50 g/ml). Protein overexpression was induced by addi-
tion of 0.2 mM isopropyl-α-D-thiogalactopyranoside (IPTG), and
cell growth continued at 16°C overnight. Ni2+-NTA affinity chroma-
tography purification was performed according to the manufactur-
er’s protocols (Novagen). The harvested cells were resuspended in
50 ml 1× binding buffer (20 mM Tris-HCl [pH 7.9], 0.5 M NaCl,
5 mM imidazole, and 10% glycerol) and disrupted by sonication.
N-terminally His6-tagged proteins were purified in one step by Ni2+-
NTA affinity column and exchanged into storage buffer by ultra-
filtration. The purified proteins were stored in appropriate buffers
(see below) containing 50% glycerol at –20°C, except BtrI and BtrV,
which were stored at 4°C: apo-BtrI, 50 mM HEPES (pH 7.0), 50 mM
NaCl, 2 mM DTT, and 0.5 mM EDTA; Sfp, 50 mM HEPES (pH 7.6)
and 200 mM NaCl; BtrJ, 50 mM HEPES (pH 7.6), 50 mM KCl, 5 mM
MgCl2, 5 mM DTT, and 0.5 mM EDTA; BtrK, 50 mM HEPES (pH 7.8)
and 2 mM DTT; BtrO, 50 mM HEPES (pH 7.6); BtrV, 50 mM Tris-HCl
(pH 7.5) and 50 mM NaCl.
LC-ESI-MS Analysis of Enzyme Assays
Online LC-ESI-MS (helium as collision gas) analysis of protein sam-
ples was performed on a Finnigan LCQ (Thermo Finnigan) coupledwith an HP1100 HPLC system (Agilent). Samples were separated
on a 4.6 × 250 mm Jupiter 5 C4 column (Phenomenex) by the
following gradient at a flow rate of 0.2 ml/min and column temper-
ature of 40°C: 0–5 min 5% B, 5–6 min 5%–35% B, 6–31 min 35%–
65% B, 31–36 min 65% B, and 36–41 min 65%–95% B (buffer A,
H2O with 0.1% TFA; buffer B, CH3CN with 0.1% TFA). Absorbance
at 214 nm was monitored. Mass spectra were acquired from 600 to
2000 Da.
In Vitro 4-Phosphopantetheinylation of Apo-BtrI
A reaction mixture (total volume 10 l) containing 50 mM HEPES
(pH 7.0), 5 mM DTT, 1 mM Coenzyme A or acyl-CoA, 1 mM MgCl2,
0.1–0.5 nmol Sfp, and 0.5–1.0 nmol apo-BtrI was incubated at 37°C
for 15–30 min and analyzed directly by LC-ESI-MS.
In Vivo 4-Phosphopantetheinylation of Apo-BtrI
The plasmid for coexpression of the genes btrI and Sfp was con-
structed as follows: PCR product of the gene sfp fused with the T7
promoter, lac operon, and T7 terminator was amplified from the
pET28-a(+)-derived plasmid pSfp with pfu polymerase. The SphI
restriction site was introduced to both primers (underlined), the
forward CoI-1 5#-GTAGGAGCATGCTTAATACGACTCACTATA-GGG
GAA-3# and the reverse CoI-2 5#-TGAGTTGCATGCAAAAAACCCC
TCAAGACCCGTTTA-3#. The digested PCR product was cloned
into the pET-28a(+)-derived plasmid pBtrI with the SphI site, yield-
ing the coexpression plasmid pCo-I, which contains both btrI and
Sfp genes each under the control of their own T7 promoter. Holo-
BtrI was overexpressed and purified as described above. The mo-
lecular mass was confirmed by online LC-ESI-MS analysis.
Enzymatic Assays of BtrJ
The γ-L-glutamylation activity of BtrJ was assayed in a typical 50
l reaction containing 10 mM L-Glu, 5 mM MgCl2, 5 mM MnCl2, 5
mM ATP, 50 mM KCl, 1 mM DTT, 1–2 nmol holo-BtrI, and 0.1–0.5
nmol BtrJ in 50 mM HEPES buffer (pH 7.6).
The L-glutamate-dependent production of ADP by BtrJ was cou-
pled with reactions of pyruvate kinase and L-lactate dehydroge-
nase and monitored by the oxidation of NADH with UV/Visible
spectrophotometry at 340 nm. A 1 ml reaction contained 50 mM
HEPES (pH 7.6), 20 mM KCl, 5 mM MgCl2, 2 mM DTT, 2 mM ATP,
10 mM MnCl2, 0.5 mM phospho(enol)pyruvate (PEP), 0.15 mM
NADH, 10 units of pyruvate kinase (type VII from rabbit muscle), 10
units of L-lactate dehydrogenase (type II from rabbit muscle), 0.5–
5.0 mol BtrJ, and 5–50 mM L-Glu. The mixture was preincubated
without L-Glu at 25°C for 5 min and transferred to a 1 ml disposable
polystyrene cuvette (Fisher). The reaction was incubated at 25°C
and initiated by addition of L-Glu. The decrease of absorbance at
340 nm was recorded on a CARY 100 Bio spectrophotometer
(Varian).
Enzymatic Assays of BtrK
To the γ-L-glutamylation reaction described above, 10–50 pmol
BtrK to a final volume of 55 l was added. The reaction was incu-
bated at 30°C for 30 min and analyzed directly by LC-ESI-MS. 100
mM EDTA (pH 7.8) was added to the γ-L-glutamylation reaction to
a final concentration of 10 mM prior to addition of BtrK to detect
GABA-S-BtrI.
Determination of BtrV FMN Cofactor
BtrV in 500 l solution (140 M) was denatured by addition of ace-
tone. Upon removal of acetone, the supernatant was analyzed by
UV-visible spectrophotometry and LC-ESI-MS on a reverse phase
Prodigy C18 column (250 × 4.6 mm, Phenomenex).
Enzymatic Assay of BtrV
A typical 1 ml reaction mixture was composed of 200 M NAD(P)H,
10 M FMN or FAD, and 715 nmol BtrV in 45 mM Tris-HCl buffer
(pH 7.5). Reaction progress was followed spectrophotometrically
at 340 or 375 nm at 25°C.
Kinetic Studies of BtrV
Kinetic parameters were measured in the presence of the external
electron acceptor iodonitrotetrazolium chloride (INT). The initial
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674rate of reaction was measured at 530 nm in a 1 ml reaction contain-
ing FMN or FAD (10 M), BtrV (14.8 nM), INT (1 mM), and various
concentration of NADH or NADPH in 20 mM sodium acetate buffer
(pH 5.0) at 530 nm at 25°C.
Enzymatic Assay of BtrO/BtrV
γ-L-Glu-GABA-S-BtrI and GABA-S-BtrI were prepared in a 60 l
reaction immediately before use. The reaction was initiated by add-
ing 10 M FMN, 2 mM NADH, 10–50 pmol BtrO, 1–5 pmol BtrV, and
incubated at 30°C for 30 min.
Monooxygenation of Butyryl-S-BtrI by BtrO/BtrV
A standard 10 l butyrylation reaction of BtrI contained 0.5–2 nmol
apo-BtrI, 0.1–0.5 nmol Sfp, 1 mM MgCl2, 5 mM DTT, and 1 mM
butyryl-CoA in 50 mM HEPES buffer (pH 7.0) and was incubated at
37°C for 15 min. 10 M FMN, 2 mM NADH, 10–50 pmol BtrO, and
1–5 pmol BtrV were added, and the reaction was continued at 37°C
for 30 min.
1
Determination of the Position and Stereochemistry
of BtrO/BtrV Hydroxylation
α-hydroxy-butyryl-S-BtrI was produced in a scaled-up 3 ml reac- 1
tion that contained 150 nmol apo-BtrI at 30°C for 1 hr. A control
reaction was set up without butyryl-CoA. A few drops of 5 M NaOH
were added, and the mixture was incubated at 40°C for 30 min.
Proteins were removed by centrifugation, and α-hydroxybutyrate
was extracted from the supernatant as described in the literature 1
[48]. The extracts were redissolved in 100 l 50 mM HEPES buffer
(pH 7.6) and incubated with 1 mM NAD+ and 10 units D- or L-lactate
dehydrogenase at 25°C. The reaction was monitored at 340 nm
over 70 min.
1
Synthesis of GABA-CoA and -L-Glu-CoA
N-Boc-L-glutamic acid α-tert-butyl ester or N-Boc-γ-aminobutyric
1acid (0.7 mmol) was dissolved in 5 ml distilled THF under nitrogen.
The solution was cooled in an ice bath, and ethylchloroformate (70
l) was added. The reaction was stirred for 5 min at 0°C, and then
coenzyme A (0.5 mmol) was added in 3.5 ml of 0.3 M NaOH solu-
1tion. The reaction continued to stir for 1 hr at room temperature
and then was neutralized with 6 M HCl and concentrated in vacuo.
After lyophilization, the resulting white solid was purified by HPLC
with a preparative C18 column with a gradient of 0%–100% buffer
1B over 30 min (buffer A, 0.1% aqueous TFA; buffer B, 100% metha-
nol). Product elution was monitored at 214 nm. Deprotection of the
product was carried out in 1 ml 100% TFA at room temperature for
1 hr. The finished reacton was diluted with water to 4 ml and puri-
1fied by HPLC as above. Product mass was confirmed by ESI-MS.
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